Health Care & Life Sciences » Pharmaceuticals | Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals Inc.
Stock Exchange NYSE
EPS
$0.35
Market Cap
$53.34 M
Shares Outstanding
31.75 M
Public Float
31.01 M

Profile

Address
15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Website http://www.rexahn.com
Updated 09/14/2018
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems.

Financials

View All
Created with Highcharts 5.0.14Rexahn Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.9 4999 49918 52118 52114 38414 3849 3079 30725 29425 2942013201420152016201705k10k15k20k25k30k

Peter David Suzdak
Chief Executive Officer & Director
Peter C. Brandt
Chairman